Mechanism of Formation of HCl (Gastric Acid Secretion)

1. The Parietal Cell - The Source

• Yamada's Textbook of Gastroenterology, 7th ed.

2. The Molecular Mechanism - H+/K+-ATPase (Proton Pump)

1. Resting state: The H+/K+-ATPase is stored in intracellular tubulovesicles in the cytoplasm. The pump is inactive.
2. Activation signal: When stimulated (by acetylcholine, gastrin, or histamine), intracellular signaling cascades are triggered (see below), causing the tubulovesicles to undergo morphological change.
3. Membrane translocation: The tubulovesicles fuse with the apical secretory canaliculi, forming an extensive canalicular system that is 6-10 times larger in surface area than in the resting cell. The H+/K+-ATPase is then inserted into this canalicular membrane.
4. Ion exchange: In the presence of luminal K+ ions, the pump secretes H+ (hydronium ions) into the lumen in exchange for K+ - an electroneutral ion exchange. This pumps H+ against an enormous concentration gradient.
5. Chloride secretion: Apical Cl- channels on the canalicular membrane allow Cl- to flow into the lumen, where it combines with the secreted H+ to form HCl.
6. Bicarbonate exchange: For every H+ secreted, one HCO3- is exported at the basolateral membrane in exchange for Cl- (via Cl-/HCO3- exchanger). This Cl- is then available for apical export. The basolateral HCO3- release into the blood causes the post-prandial "alkaline tide."

• Sabiston Textbook of Surgery, 11th ed.

3. Intracellular Signal Transduction Pathways

• Yamada's Textbook of Gastroenterology, Sabiston Textbook of Surgery

4. Three Phases of Gastric Acid Secretion

• Yamada's Textbook of Gastroenterology, 7th ed.

Factors Influencing HCl Formation

Stimulatory Factors

• Released from vagal and parasympathetic ganglion cells
• Acts directly on M3 receptors on parietal cells (via IP3/Ca2+ pathway)
• Also acts on M2/M4 receptors on D cells to inhibit somatostatin, removing the brake on acid secretion
• Central vagal activity (thought, smell, taste of food) accounts for approximately half of post-meal acid secretion

• Produced by G cells in the gastric antrum (also small intestine, pancreas)
• Active forms: G17 (dominant post-meal) and G34 (dominant during fasting)
• Acts directly on parietal cell CCK-B receptors and indirectly by stimulating histamine release from ECL cells
• Stimulated by: ACh, GRP, secretin, 5-HT, amino acids, proteins, calcium, capsaicin, fermented alcoholic drinks

• Stored in ECL cells (enterochromaffin-like cells) and mast cells in the oxyntic mucosa
• Acts via H2 receptors on parietal cells (cAMP pathway)
• H2 receptor antagonists almost completely abolish acid secretion in response to both gastrin and ACh, making histamine an obligate intermediary
• Histamine release from ECL cells is stimulated by gastrin, VIP, ghrelin, ACh, and epinephrine

• A 28-amino acid peptide from P/D1 cells of the fundal oxyntic glands
• Upregulated during fasting; increases gastric acid secretion via vagal and histamine-mediated mechanisms

• Orexin-A (via gastrin-mediated mechanism)
• PACAP (complex, ECL cell-mediated effects)
• b-adrenergic agonists

Inhibitory Factors

• Produced by D cells in the gastric antrum and corpus
• Acts via SSTR2 receptors (Gi protein) on G cells (inhibits gastrin), ECL cells (inhibits histamine), and parietal cells directly
• Release is stimulated by: luminal acidity, gastrin, CGRP, GRP, VIP, secretin, b-adrenergic agonists
• Represents the primary negative feedback - as luminal pH drops, somatostatin rises and shuts down further acid secretion

• Secretin - released in response to acid in the duodenum; stimulates somatostatin release
• CCK - inhibits acid by stimulating somatostatin release
• GLP-1, PYY, glucagon, neurotensin - various anti-secretory mechanisms
• ANP, EGF, leptin, TGF-a - additional inhibitory peptides
• Prostaglandins - inhibit histamine release from ECL cells

• When gastric pH falls below 3, direct stimulation of antral D cells releases somatostatin, which inhibits gastrin from G cells - classic negative feedback

• H2 receptor antagonists (famotidine, cimetidine) block the histamine pathway
• Proton pump inhibitors (omeprazole, lansoprazole) irreversibly block H+/K+-ATPase
• Potassium-competitive acid blockers (PCABs) - newer agents targeting the proton pump

Note on GERD (Gastroesophageal Reflux Disease)

Definition

• Mulholland and Greenfield's Surgery, 7th ed.; Robbins & Kumar Basic Pathology

Pathophysiology

• Adequate LES length, with sufficient intra-abdominal portion
• Adequate sphincter pressure (normal: 10-45 mmHg)
• Correct angle of His and normal crural anatomy
• Appropriate (but not excessive) LES relaxations during swallowing
• Normal esophageal motility

• Fischer's Mastery of Surgery, 8th ed.

Contributing Factors

Clinical Features

• Heartburn (pyrosis) - the most common symptom; retrosternal burning
• Regurgitation - sour/bitter taste of gastric contents rising to the pharynx
• Dysphagia - difficulty swallowing (may suggest stricture)
• Chest pain - can mimic cardiac disease
• Extra-esophageal manifestations: chronic cough, asthma/wheeze (acid micro-aspiration or vagally mediated bronchospasm), hoarseness, laryngitis, dental enamel erosion (palatal surfaces of maxillary teeth)

• Robbins & Kumar; Sleisenger and Fordtran's GI and Liver Disease

Complications

Histology of GERD

• Mild GERD: mucosa often unremarkable
• Established GERD: intraepithelial eosinophils (early), followed by neutrophil infiltration (more severe injury)
• Basal zone hyperplasia and elongation of lamina propria papillae
• Symptom severity does not correlate closely with histological severity

Treatment

1. Lifestyle modifications: Weight loss (proven to reduce GERD in RCTs), elevation of head of bed, avoiding trigger foods (fat, alcohol, chocolate, mint), not eating 2-3 hours before lying down, smoking cessation
2. Antacids: For intermittent mild symptoms; immediate but short-lived relief
3. H2 receptor antagonists (famotidine): Block the histamine pathway; moderate efficacy; tachyphylaxis develops with chronic use
4. Proton pump inhibitors (PPIs) (omeprazole, lansoprazole, esomeprazole): Most effective medical therapy; block the H+/K+-ATPase irreversibly; once-daily dosing heals erosive esophagitis and provides symptom relief in the vast majority
5. Surgical therapy (Nissen fundoplication, laparoscopic): For patients with refractory symptoms, large hiatal hernias, or Barrett's esophagus who fail or cannot tolerate medical therapy

• Robbins & Kumar Basic Pathology; Katzung's Basic and Clinical Pharmacology, 16th ed.; Fischer's Mastery of Surgery, 8th ed.; Yamada's Textbook of Gastroenterology, 7th ed.